MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q2
hinzugefügt 03.08.2023
Paratek Pharmaceuticals Operativer Cashflow 2011-2026 | PRTK
Operativer Cashflow Jährlich Paratek Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -66.1 M | -48.3 M | -103 M | -134 M | -81.2 M | -78.6 M | - | - | - | -14.8 M | -15.2 M | -5.71 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -5.71 M | -134 M | -60.8 M |
Operativer Cashflow Vierteljährlich Paratek Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 11.1 M | - | -46 M | - | -19.1 M | - | -28.5 M | - | -21.5 M | - | -79.6 M | -50.7 M | -30.3 M | - | -98.5 M | -70.4 M | -35.8 M | - | -62.2 M | -41.7 M | -19.1 M | - | -56.2 M | -40.7 M | - | - | - | - | - | - | - | - | - | - | - | - | -131 K | - | -9.36 M | -7.55 M | -4.27 M | - | -1.68 M | -8.18 M | -3.55 M | - | -13.1 M | -7.83 M | -4.29 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 11.1 M | -98.5 M | -28.8 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Veracyte
VCYT
|
136 M | $ 31.01 | -5.46 % | $ 2.44 B | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
-19.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Vir Biotechnology
VIR
|
-392 M | $ 8.47 | -5.47 % | $ 1.17 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
-452 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Viking Therapeutics
VKTX
|
-279 M | $ 32.67 | -4.61 % | $ 3.68 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
-80.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-235 M | - | - | $ 546 M | USA |
 |
Viridian Therapeutics
VRDN
|
-276 M | $ 27.39 | -2.87 % | $ 2.79 B | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
3.63 B | $ 437.99 | -3.47 % | $ 112 B | USA |
 |
Avid Bioservices
CDMO
|
11 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Verastem
VSTM
|
-138 M | $ 5.01 | -5.29 % | $ 347 M | USA |
 |
VistaGen Therapeutics
VTGN
|
-42.1 M | $ 0.56 | -7.23 % | $ 17.3 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-46 M | $ 12.88 | -7.74 % | $ 1.95 B | USA |
 |
vTv Therapeutics
VTVT
|
-16 M | $ 38.69 | 2.35 % | $ 152 M | USA |
 |
Voyager Therapeutics
VYGR
|
-132 M | $ 3.97 | -4.0 % | $ 233 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alnylam Pharmaceuticals
ALNY
|
524 M | $ 320.49 | -2.34 % | $ 42 B | USA |
 |
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-92.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-75.6 M | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-13 M | $ 1.07 | -1.82 % | $ 21.9 M | Israel |
 |
Enochian Biosciences
ENOB
|
-7.87 M | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Equillium
EQ
|
-22.7 M | $ 1.93 | -6.31 % | $ 111 M | USA |
 |
Amgen
AMGN
|
9.96 B | $ 351.01 | -0.61 % | $ 189 B | USA |